Artelo Biosciences, Inc. Enters into Subscription Agreement for Convertible Notes and Warrants

On October 28, 2025, Artelo Biosciences, Inc. entered into a Subscription Agreement with certain investors, issuing convertible notes with an aggregate principal amount of $690,154.69 and warrants to purchase 438,182 shares of common stock at $3.40 per share. The notes accrue interest at 12% per annum, adjustable to 20% upon an event of default, and are due six months after the closing date. The warrants are exercisable for five years and include anti-dilution provisions. The company agreed to file a registration statement for the resale of the shares issuable upon conversion of the notes and exercise of the warrants. Certain directors and officers participated in the offering, which was approved by the board.